Table 2.
Lymphedema Staging: Descriptive Statistics (Per-Protocol Analysis)
| Pretreatment | 3-Month Follow-up | 12-Month Follow-up | 24-Month Follow-up | |
|---|---|---|---|---|
| Treatment A: doxycycline (200 mg/d) | ||||
| CFA positive and negative | ||||
| Patients, No. | 46 | 44 | 45 | 41 |
| LE stage, mean ± SD (range) | 2.6 ± 0.7 (1–5) | 2.6 ± 0.8 (1–6) | 2.4 ± 1.2 (0–6) | 2.2 ± 1.2 (0–6) |
| LE stage, median (25th; 75th percentile) | 3 (2; 3) | 3 (2; 3) | 2 (2; 3) | 2 (1; 3) |
| Pa | .48 | .067 | .002 | |
| Subgroup: CFA positive before treatment | ||||
| Patients, No. | 19 | 19 | 19 | 17 |
| LE stage, mean ± SD (range) | 2.6 ± 0.8 (1–5) | 2.6 ± 1.1 (1–6) | 2.6 ± 1.6 (0–6) | 2.2 ± 1.4 (0–6) |
| LE stage, median (25th; 75th percentile) | 3 (2; 3) | 3 (2; 3) | 3 (2; 3) | 2 (1; 3) |
| Pa | .564 | .861 | .058 | |
| Subgroup: CFA negative before treatment | ||||
| Patients, No. | 27 | 25 | 26 | 24 |
| LE stage, mean ± SD (range) | 2.6 ± 0.7 (2–4) | 2.5 ± 0.7 (1–4) | 2.2 ± 0.9 (0–4) | 2.1 ± 1.0 (0–4) |
| LE stage, median (25th; 75th percentile) | 3 (2; 3) | 2 (2; 3) | 2 (2; 3) | 2 (1.25; 3) |
| Pa | .18 | .02 | .013 | |
| Treatment B: amoxicillin (1000 mg/d) | ||||
| CFA positive and negative | ||||
| Patients, No. | 35 | 34 | 31 | 31 |
| LE stage, mean ± SD (range) | 2.5 ± 0.7 (1–5) | 2.5 ± 0.7 (1–6) | 2.7 ± 1.3 (1–6) | 3.0 ± 1.4 (1–6) |
| LE stage, median (25th; 75th percentile) | 2 (2; 3) | 2 (2; 3) | 2 (2; 3) | 2 (2; 4) |
| Pa | 1.0 | .38 | .012 | |
| Subgroup: CFA positive before treatment | ||||
| Patients, No. | 13 | 13 | 11 | 12 |
| LE stage, mean ± SD (range) | 2.4 ± 0.7 (1–3) | 2.4 ± 0.7 (1–3) | 2.3 ± 0.8 (1–3) | 2.7 ± 1.0 (1–4) |
| LE stage, median (25th; 75th percentile) | 2 (2; 3) | 2 (2; 3) | 2 (2; 3) | 2.5 (2; 3.75) |
| Pa | 1.0 | .157 | .083 | |
| Subgroup: CFA negative before treatment | ||||
| Patients, No. | 22 | 21 | 20 | 19 |
| LE stage, mean ± SD (range) | 2.6 ± 0.7 (2–5) | 2.6 ± 1.0 (1–6) | 2.9 ± 1.5 (1–6) | 3.2 ± 1.6 (1–6) |
| LE stage, median (25th; 75th percentile) | 2 (2; 3) | 2 (2; 3) | 2 (2; 3) | 2 (2; 5) |
| Pa | 1.0 | .129 | .04 | |
| Treatment C: placebo | ||||
| CFA positive and negative | ||||
| Patients, No. | 38 | 36 | 34 | 36 |
| LE stage, mean ± SD (range) | 2.8 ± 0.8 (2–5) | 3.0 ± 1.3 (1–6) | 3.4 ± 1.6 (0–6) | 3.6 ± 1.5 (0–6) |
| LE stage, median (25th; 75th percentile) | 3 (2; 3) | 3 (2; 3) | 3 (2; 5) | 3 (3; 4.75) |
| Pa | .206 | .02 | .001 | |
| Subgroup: CFA positive before treatment | ||||
| Patients, No. | 14 | 13 | 11 | 13 |
| LE stage, mean ± SD (range) | 2.9 ± 1.2 (2–5) | 3.1 ± 1.4 (2–6) | 3.7 ± 2.0 (0–6) | 3.6 ± 2.0 (0–6) |
| LE stage, median (25th; 75th percentile) | 2.5 (2; 3.5) | 3 (2; 4) | 3 (2; 6) | 3 (2; 6) |
| Pa | .317 | .141 | .168 | |
| Subgroup: CFA negative before treatment | ||||
| Patients, No. | 24 | 23 | 23 | 23 |
| LE stage, mean ± SD (range) | 2.8 ± 0.7 (2–5) | 2.9 ± 1.2 (1–6) | 3.3 ± 1.4 (2–6) | 3.6 ± 1.2 (2–6) |
| LE stage, median (25th; 75th percentile) | 3 (2; 3) | 3 (2; 3) | 3 (2; 3) | 3 (3; 4) |
| Pa | .317 | .046 | .001 |
Abbreviations: CFA, circulating filarial antigen; LE, lymphedema; SD, standard deviation.
a P value for comparison between staging before treatment and at follow-up time point (Wilcoxon signed rank test).